The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing
Cancer Medicine · 2024
DOI: 10.1002/cam4.70416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zuoyao Long und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Hospital of Northern Theater Command, Shenyang, China. Hauptthemen laut MEDLINE: Osteosarcoma, Quinolines, Indoles, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Liaoning Province.
Abstract (Originalsprache)
Background
The aim of this study was to analyze the potential therapeutic targets of anlotinib using the patient‐derived xenografts (PDX) and evaluate the efficacy of the combination of chemotherapy and anlotinib in osteosarcoma patients before surgery.
Methods
Forty‐three osteosarcoma specimens were used to establish the PDX model in mice, resulting in Twenty‐one PDX successful models. Eventually, six models were randomly selected for the pharmacodynamic experiment. The tumor‐bearing mice were randomly divided into the anlotinib (3 mg/kg) and placebo groups ( n = 5 each). After treatment, the tumors were harvested and analyzed by immunohistochemistry (IHC) and western blotting.
Results
In PDX model establishment, the tumors from donors with relapse, metastasis or chemoresistance demonstrated higher engraftment capacity. Histology results suggested that anlotinib significantly inhibited the growth of osteosarcoma by inducing mitotic arrest, necrosis and apoptosis, and selective against tumors with high expression of VEGFR2, PDGFRβ and CD31. Based on these results, five osteosarcoma patients who had progressed during NAC were treated with the combination of anlotinib and chemotherapy before surgery, which led to tumor regression in four patients. Next‐generation sequencing showed that most patients with tumor reduction expressed medium or high levels of VEGFR2 and PDGFRβ mRNA. The toxicities were tolerable.
Conclusions
In conclusion, osteosarcoma with high expression of VEGFR2, PDGFRβ and CD31 is more sensitive to anlotinib. However, the potential of synergistic effect of anlotinib and chemotherapy in osteosarcoma patients needs further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Hospital of Northern Theater Command, Shenyang, China.
- Xijing Hospital, The Air Force Military Medical University, Xi'an, China.
ORCID-Profile: Zuoyao Long
Förderung
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Long, Z., Lu, Y., Li, M., Li, J., Chen, G., Wang, F., Wang, Q., Xiang, L., & Wang, Z. (2024). The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing. Cancer Medicine. https://doi.org/10.1002/cam4.70416
Vancouver
Long Z, Lu Y, Li M, Li J, Chen G, Wang F, et al. The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing. Cancer Medicine. 2024. doi:10.1002/cam4.70416
BibTeX
@article{Long2024,
author = {Long, Zuoyao and Lu, Yajie and Li, Minghui and Li, Jing and Chen, Guojing and Wang, Fengwei and Wang, Qi and Xiang, Liangbi and Wang, Zhen},
title = {The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient‐Derived Xenografts and Next‐Generation Sequencing},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70416}
}
EUVIMED